The 36-month beta value for LEGN is also noteworthy at 0.15. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 10 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for LEGN is 181.93M, and at present, short sellers hold a 12.61% of that float. The average trading volume of LEGN on January 03, 2025 was 1.46M shares.
LEGN) stock’s latest price update
Legend Biotech Corp ADR (NASDAQ: LEGN) has experienced a rise in its stock price by 0.84 compared to its previous closing price of 34.73. However, the company has seen a gain of 6.83% in its stock price over the last five trading days. globenewswire.com reported 2024-12-19 that SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT.
LEGN’s Market Performance
Legend Biotech Corp ADR (LEGN) has seen a 6.83% rise in stock performance for the week, with a -19.83% decline in the past month and a -26.72% plunge in the past quarter. The volatility ratio for the week is 3.32%, and the volatility levels for the past 30 days are at 4.88% for LEGN. The simple moving average for the past 20 days is -0.79% for LEGN’s stock, with a -25.79% simple moving average for the past 200 days.
Analysts’ Opinion of LEGN
Many brokerage firms have already submitted their reports for LEGN stocks, with Redburn Atlantic repeating the rating for LEGN by listing it as a “Buy.” The predicted price for LEGN in the upcoming period, according to Redburn Atlantic is $86 based on the research report published on October 08, 2024 of the previous year 2024.
Truist, on the other hand, stated in their research note that they expect to see LEGN reach a price target of $88. The rating they have provided for LEGN stocks is “Buy” according to the report published on June 17th, 2024.
H.C. Wainwright gave a rating of “Buy” to LEGN, setting the target price at $73 in the report published on May 24th of the previous year.
LEGN Trading at -11.03% from the 50-Day Moving Average
After a stumble in the market that brought LEGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.06% of loss for the given period.
Volatility was left at 4.88%, however, over the last 30 days, the volatility rate increased by 3.32%, as shares sank -17.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.48% lower at present.
During the last 5 trading sessions, LEGN rose by +6.50%, which changed the moving average for the period of 200-days by -44.43% in comparison to the 20-day moving average, which settled at $35.29. In addition, Legend Biotech Corp ADR saw 7.62% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LEGN starting from Huang Ying, who proposed sale 63,061 shares at the price of $32.45 back on Dec 24 ’24. After this action, Huang Ying now owns shares of Legend Biotech Corp ADR, valued at $2,046,512 using the latest closing price.
Macomber Lori, the Officer of Legend Biotech Corp ADR, proposed sale 189 shares at $32.45 during a trade that took place back on Dec 24 ’24, which means that Macomber Lori is holding shares at $6,134 based on the most recent closing price.
Stock Fundamentals for LEGN
Current profitability levels for the company are sitting at:
- -0.54 for the present operating margin
- 0.61 for the gross margin
The net margin for Legend Biotech Corp ADR stands at -0.67. The total capital return value is set at -0.19. Equity return is now at value -28.35, with -19.47 for asset returns.
Based on Legend Biotech Corp ADR (LEGN), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -0.52. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is -12.59.
Currently, EBITDA for the company is -477.87 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 12.12. The receivables turnover for the company is 5.0for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.98.
Conclusion
In summary, Legend Biotech Corp ADR (LEGN) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
